Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data [Yahoo! Finance]
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: Yahoo! Finance
20, Lake Street analyst Thomas Flaten raised the firm's price target on Evaxion Biotech to $11 from $6 and kept a Buy rating on the shares. This sentiment was announced after the company announced two-year Phase 2 data for its personalized cancer vaccine, EVX-01, in advanced melanoma. Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data EVX-01 is a personalized peptide-based cancer vaccine for first-line treatment of multiple advanced solid cancers and is Evaxion's lead clinical asset. Flaten informed investors that the two-year data for EVX-01 and Merck & Co. Inc.'s (NYSE: MRK ) option exercise for EVX-B3 both serve to further validate Evaxion's platform. Evaxion (NASDAQ:EVAX) is a clinical-stage biotech company that develops AI-powered immunology vaccines. It was formerly known as Evaxion Biotech and changed its name to Evaxion in May 2025. Merck & Co. Inc. (NYSE:MRK) is a healthcare company that offers human health pharmaceuticals, ve
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1GlobeNewswire
- Evaxion announce 2026 financial calendarGlobeNewswire
- Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]Yahoo! Finance
- Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01GlobeNewswire
- Evaxion announces business update and third quarter 2025 financial resultsGlobeNewswire
EVAX
Sec Filings
- 11/21/25 - Form F-1
- 11/20/25 - Form 6-K
- 11/18/25 - Form 6-K
- EVAX's page on the SEC website